June 1, 2023 Issue of JAMA Oncology

June 2023, Vol 9, No. 6, Pages 743-876

Original Investigation

Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation

Shaobo Mo, MD; Li Ye, MD; Dongyang Wang, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):770-778. doi:10.1001/jamaoncol.2023.0425

This cohort study investigates the effectiveness of circulating tumor DNA methylation in early detection of colorectal cancer recurrence.

Editorial
Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?
Juan Ruiz-Bañobre, MD, PhD; Ajay Goel, PhD

JAMA Oncol

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial

Kevin J. Harrington, MBBS, PhD; Robert L. Ferris, MD, PhD; Maura Gillison, MD, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2023;9(6):779-789. doi:10.1001/jamaoncol.2023.0147

This randomized clinical trial investigates whether first-line treatment with nivolumab plus ipilimumab vs nivolumab alone improves objective response rate in adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Invited Commentary
Combination Immunotherapy in Head and Neck Cancer鈥擟heckmate or a Draw?
Marshall Posner, MD

JAMA Oncol

Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum

Zoe F. Cairncross, MPH; Lorraine Shack, PhD; Gregg Nelson, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):791-799. doi:10.1001/jamaoncol.2023.0339

This retrospective cohort study assesses mortality and survival in premenopausal women with pregnancy-associated cancers, with a particular focus on cancers other than those of the breast.

Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial

Samuel Ryu, MD; Snehal Deshmukh, MS; Robert D. Timmerman, MD; et al.

Abstract Full Text

free access has audio

JAMA Oncol. 2023;9(6):800-807. doi:10.1001/jamaoncol.2023.0356

This randomized clinical trial assesses whether patient-reported pain relief was improved with stereotactic radiosurgery compared with conventional external beam radiotherapy for patients with 1 to 3 sites of vertebral metastases.

Podcast: Radiosurgery of Spine Metastasis鈥擭RG/RTOG 0631 RCT Final Results

Longitudinal Analysis of Change in Mammographic Density in Each Breast and Its Association With Breast Cancer Risk

Shu Jiang, PhD; Debbie L. Bennett, MD; Bernard A. Rosner, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2023;9(6):808-814. doi:10.1001/jamaoncol.2023.0434

This nested case-control cohort study evaluates the association between change in mammographic density in each breast over time and risk of subsequent breast cancer.

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial

Tufia C. Haddad, MD; Vera J. Suman, PhD; Antonino B. D鈥橝ssoro, MD, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2023;9(6):815-824. doi:10.1001/jamaoncol.2022.7949

This randomized clinical trial examines the effect of adding fulvestrant to alisertib on objective tumor response rates in endocrine-resistant metastatic breast cancer.

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial

Chad Tang, MD; Alexander D. Sherry, MD; Cara Haymaker, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):825-834. doi:10.1001/jamaoncol.2023.0161

This randomized clinical trial examines whether the addition of metastasis-directed therapy (MDT) to intermittent hormone therapy in men with oligometastatic prostate cancer improves progression-free survival.

Brief Report

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab

Adrienne G. Waks, MD; Esther R. Ogayo, BS; Laia Paré, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):835-840. doi:10.1001/jamaoncol.2023.0181

This clinical trial examines the ability of the HER2DX assay to predict the likelihood of pathologic complete response in patients with early-stage ERBB2鈥損ositive breast cancer who are receiving deescalated neoadjuvant therapy.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

Coralia Bueno-Muiño, MD; Isabel Echavarría, MD; Sara López-Tarruella, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):841-846. doi:10.1001/jamaoncol.2023.0187

This diagnostic study aims to determine if use of the HER2DX genomic assay (Reveal Genomics) in pretreatment baseline tissue samples of patients with ERBB2-positive breast cancer is associated with response to neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab.

Association Between 5伪-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis

Michael Baboudjian, MD; Bastien Gondran-Tellier, MD; Charles Dariane, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):847-850. doi:10.1001/jamaoncol.2023.0260

This systematic review and meta-analysis systematically evaluates the current evidence regarding 5伪-reductase inhibitor use and prostate cancer mortality.

Research Letter

Enrollment Barriers for Molecular Targeted Trials

Koosha Paydary, MD; Alli DeLuca, MD; Rahul Aggarwal, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):863-864. doi:10.1001/jamaoncol.2023.0248

This quality improvement study examines the difficulties of patient accrual among patients with cancer and SETD2 variants.

Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder

Manish Agrawal, MD; Ezekiel Emanuel, MD, PhD; Brian Richards, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):864-866. doi:10.1001/jamaoncol.2023.0351

This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.

Review

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review

Debra L. Richardson, MD; Ramez N. Eskander, MD; David M. O鈥橫alley, MD

Abstract Full Text

has active quiz

JAMA Oncol. 2023;9(6):851-859. doi:10.1001/jamaoncol.2023.0197

This review summarizes the current and evolving treatment landscape for platinum-resistant ovarian cancer and highlights the development of promising novel compounds.

JAMA Oncology Clinical Challenge

Nonhealing Cutaneous Ulcers in a Patient With Myelodysplastic Syndrome

Aryanna I. Jordan, MD; Ling Zhang, MD; Seongseok Yun, MD, PhD

Abstract Full Text

has active quiz

JAMA Oncol. 2023;9(6):860-861. doi:10.1001/jamaoncol.2023.0193

A 75-year-old man with myelodysplastic syndrome that has been well controlled with lenalidomide develops multiple nonhealing cutaneous ulcers. What is your diagnosis?

Viewpoint

鈥淵ou鈥檝e Got Mail鈥濃€擱eceiving Bad News Through a Patient Portal

Keith M. Bellizzi, PhD, MPH

Abstract Full Text

JAMA Oncol. 2023;9(6):757-758. doi:10.1001/jamaoncol.2023.0422

This Viewpoint discusses the impersonalization of delivering bad news to patients through a patient portal rather than in person.

Molecular Marker Testing in Curable Non鈥揝mall Cell Lung Cancer鈥擯ractice Necessarily Precedes Data

Charu Aggarwal, MD, MPH; Howard (Jack) West, MD

Abstract Full Text

JAMA Oncol. 2023;9(6):758-760. doi:10.1001/jamaoncol.2023.0251

This Viewpoint describes the use of broad molecular marker testing in patients with early-stage non鈥搒mall cell lung cancer

Editorial

Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

Juan Ruiz-Bañobre, MD, PhD; Ajay Goel, PhD

Abstract Full Text

JAMA Oncol. 2023;9(6):763-764. doi:10.1001/jamaoncol.2023.0329

Clinical Trial Diversity鈥擶ill We Know It When We See It?

Tanvee Varma, BA; Cary P. Gross, MD; Jennifer E. Miller, PhD

Abstract Full Text

JAMA Oncol. 2023;9(6):765-767. doi:10.1001/jamaoncol.2023.0143

This Editorial discusses the existing policy efforts in the US for ensuring adequate racial and ethnic diversity in clinical trials, identifies barriers to consistency and acceptable representation, and suggests measures to address them.

Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer鈥擯ARADIGM Shift

Hannah R. Robinson, MD; Christopher H. Lieu, MD

Abstract Full Text

JAMA Oncol. 2023;9(6):767-769. doi:10.1001/jamaoncol.2023.1088

Invited Commentary

Combination Immunotherapy in Head and Neck Cancer鈥擟heckmate or a Draw?

Marshall Posner, MD

Abstract Full Text

JAMA Oncol. 2023;9(6):789-790. doi:10.1001/jamaoncol.2023.0086

JAMA Oncology Patient Page

Blood Clots, or Thrombosis, in Patients With Cancer

Henry K. Litt, MD; Anna L. Parks, MD; Ana I. Velazquez, MD, MSc

Abstract Full Text

free access

JAMA Oncol. 2023;9(6):876. doi:10.1001/jamaoncol.2022.6892

This JAMA Oncology Patient Page explains the risk, diagnosis, treatment, and prevention of thrombosis in patients with cancer.

Cancer Care Chronicles

Different Ways of Traveling the Cancer Road鈥擠aytime Running Lights at Night?

Michael Sanatani, MMEd, MD

Abstract Full Text

JAMA Oncol. 2023;9(6):761-762. doi:10.1001/jamaoncol.2022.7143

This essay describes the reflections of an oncology ward attending physician and patients with cancer who are blindsided by cancer recurrence or progression.

Poetry and Oncology